Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul 20;11(7):e0159071.
doi: 10.1371/journal.pone.0159071. eCollection 2016.

Hba1c, Blood Pressure, and Lipid Control in People with Diabetes: Japan Epidemiology Collaboration on Occupational Health Study

Affiliations

Hba1c, Blood Pressure, and Lipid Control in People with Diabetes: Japan Epidemiology Collaboration on Occupational Health Study

Huanhuan Hu et al. PLoS One. .

Abstract

Aims: The control of blood glucose levels, blood pressure (BP), and low-density lipoprotein cholesterol (LDL-C) levels reduces the risk of diabetes complications; however, data are scarce on control status of these factors among workers with diabetes. The present study aimed to estimate the prevalence of participants with diabetes who meet glycated hemoglobin (HbA1c), BP, and LDL-C recommendations, and to investigate correlates of poor glycemic control in a large working population in Japan.

Methods: The Japan Epidemiology Collaboration on Occupational Health (J-ECOH) Study is an ongoing cohort investigation, consisting mainly of employees in large manufacturing companies. We conducted a cross-sectional analysis of 3,070 employees with diabetes (2,854 men and 216 women) aged 20-69 years who attended periodic health examinations. BP was measured and recorded using different company protocols. Risk factor targets were defined using both American Diabetes Association (ADA) guidelines (HbA1c < 7.0%, BP < 140/90 mmHg, and LDL-C < 100 mg/dL) and Japan Diabetes Society (JDS) guidelines (HbA1c < 7.0%, BP < 130/80 mmHg, and LDL-C < 120 mg/dL). Logistic regression models were used to explore correlates of poor glycemic control (defined as HbA1c ≥ 8.0%).

Results: The percentages of participants who met ADA (and JDS) targets were 44.9% (44.9%) for HbA1c, 76.6% (36.3%) for BP, 27.1% (56.2%) for LDL-C, and 11.2% (10.8%) for simultaneous control of all three risk factors. Younger age, obesity, smoking, and uncontrolled dyslipidemia were associated with poor glycemic control. The adjusted odds ratio of poor glycemic control was 0.58 (95% confidence interval, 0.46-0.73) for participants with treated but uncontrolled hypertension, and 0.47 (0.33-0.66) for participants with treated and controlled hypertension, as compared with participants without hypertension. There was no significant difference in HbA1c levels between participants with treated but uncontrolled hypertension and those with treated and controlled hypertension.

Conclusion: Data from a large working population, predominantly composed of men, suggest that achievement of HbA1c, BP, and LDL-C targets was less than optimal, especially in younger participants. Uncontrolled dyslipidemia was associated with poor glycemic control. Participants not receiving antihypertensive treatment had higher HbA1c levels.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: H. Okazaki and S. Dohi belong to Mitsui Chemicals, Inc.; T. Miyamoto, Nippon Steel & Sumitomo Metal Corporation Kimitsu Works; T. Murakami, C. Shimizu, and M. Shimizu, Keihin Occupational Health Center. K. Tomita, Mitsubishi Plastics, Inc.; S. Nagahama, All Japan Labour Welfare Foundation; M. Eguchi, T. Kochi, and I. Kabe, Furukawa Electric Co., Ltd.; A. Hori and C. Nishiura, Tokyo Gas Co., Ltd.; T. Imai and A. Okino, Azbil Corporation; N. Sasaki, Mitsubishi Fuso Truck and Bus Corporation; T. Nakagawa, S. Yamamoto, and T. Honda, Hitachi, Ltd.; A. Uehara, and M. Yamamoto, YAMAHA CORPORATION. H. Okazaki, S. Dohi, T. Murakami, C. Shimizu, and M. Shimizu, K. Tomita, M. Eguchi, T. Kochi, and I. Kabe, T. Imai and A. Okino, N. Sasaki, A. Hori, C. Nishiura, T. Nakagawa, S. Yamamoto, and T. Honda, A. Uehara, and M. Yamamoto are the health professionals in each participating company. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Similar articles

Cited by

References

    1. van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010;17 Suppl 1:S3–8. 10.1097/01.hjr.0000368191.86614.5a - DOI - PubMed
    1. International Diabetes Federation. IDF Diabetes Atlas, 6 ed. Brussels, Belgium: International Diabetes Federation, 2013.
    1. Iso H. Changes in coronary heart disease risk among Japanese. Circulation. 2008;118:2725–9. 10.1161/CIRCULATIONAHA.107.750117 - DOI - PubMed
    1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–53. - PubMed
    1. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–62. - PubMed

MeSH terms